LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 2 of total 2

Search options

  1. Article ; Online: Trichodysplasia spinulosa: a benign adnexal proliferation with follicular differentiation associated with polyomavirus.

    Lee, Yvonne Y / Tucker, Simon C / Prow, Natalie A / Setoh, Yin Xiang / Banney, Leith A

    The Australasian journal of dermatology

    2014  Volume 55, Issue 2, Page(s) e33–6

    Abstract: Trichodysplasia spinulosa is a rare polyomavirus-associated cutaneous eruption occurring in the setting of immunosuppression. Clinically it is characterised by multiple centrofacial folliculocentric papules with spinous protuberances. The histopathology ... ...

    Abstract Trichodysplasia spinulosa is a rare polyomavirus-associated cutaneous eruption occurring in the setting of immunosuppression. Clinically it is characterised by multiple centrofacial folliculocentric papules with spinous protuberances. The histopathology is distinct and treatment with antiviral agents appears to be the most effective.
    MeSH term(s) Facial Dermatoses/pathology ; Facial Dermatoses/virology ; Female ; Hair Diseases/pathology ; Hair Diseases/virology ; Hair Follicle/pathology ; Humans ; Immunocompromised Host ; Middle Aged ; Polyomavirus/genetics ; Polyomavirus/isolation & purification ; Polyomavirus Infections/complications ; Polyomavirus Infections/virology
    Language English
    Publishing date 2014-05
    Publishing country Australia
    Document type Case Reports ; Journal Article
    ZDB-ID 138052-7
    ISSN 1440-0960 ; 0004-8380
    ISSN (online) 1440-0960
    ISSN 0004-8380
    DOI 10.1111/ajd.12012
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 236: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Nicotinamide for Skin-Cancer Chemoprevention in Transplant Recipients.

    Allen, Nicholas C / Martin, Andrew J / Snaidr, Victoria A / Eggins, Renee / Chong, Alvin H / Fernandéz-Peñas, Pablo / Gin, Douglas / Sidhu, Shireen / Paddon, Vanessa L / Banney, Leith A / Lim, Adrian / Upjohn, Edward / Schaider, Helmut / Ganhewa, Aparna D / Nguyen, Jennifer / McKenzie, Catriona A / Prakash, Saurabh / McLean, Catriona / Lochhead, Alistair /
    Ibbetson, Jan / Dettrick, Andrew / Landgren, Anthony / Allnutt, Katherine J / Allison, Clare / Davenport, Rachael B / Mumford, Blake P / Wong, Brittany / Stagg, Brendan / Tedman, Alexander / Gribbin, Hannah / Edwards, Harrison A / De Rosa, Nicholas / Stewart, Thomas / Doolan, Brent J / Kok, Yonatan / Simpson, Kate / Low, Zhi M / Kovitwanichkanont, Tom / Scolyer, Richard A / Dhillon, Haryana M / Vardy, Janette L / Chadban, Steven J / Bowen, David G / Chen, Andrew C / Damian, Diona L

    The New England journal of medicine

    2023  Volume 388, Issue 9, Page(s) 804–812

    Abstract: Background: Immunosuppressed organ-transplant recipients have an increased incidence of, and mortality from, skin cancer. Nicotinamide (vitamin B: Methods: In this phase 3 trial, we randomly assigned, in a 1:1 ratio, organ-transplant recipients who ... ...

    Abstract Background: Immunosuppressed organ-transplant recipients have an increased incidence of, and mortality from, skin cancer. Nicotinamide (vitamin B
    Methods: In this phase 3 trial, we randomly assigned, in a 1:1 ratio, organ-transplant recipients who had had at least two keratinocyte cancers in the past 5 years to receive 500 mg of nicotinamide or placebo twice daily for 12 months. Participants were examined for skin lesions by dermatologists at 3-month intervals for 12 months. The primary end point was the number of new keratinocyte cancers during the 12-month intervention period. Secondary end points included the numbers of squamous-cell and basal-cell carcinomas during the 12-month intervention period, the number of actinic keratoses until 6 months after randomization, safety, and quality of life.
    Results: A total of 158 participants were enrolled, with 79 assigned to the nicotinamide group and 79 to the placebo group. The trial was stopped early owing to poor recruitment. At 12 months, there were 207 new keratinocyte cancers in the nicotinamide group and 210 in the placebo group (rate ratio, 1.0; 95% confidence interval, 0.8 to 1.3; P = 0.96). No significant between-group differences in squamous-cell and basal-cell carcinoma counts, actinic keratosis counts, or quality-of-life scores were observed. Adverse events and changes in blood or urine laboratory variables were similar in the two groups.
    Conclusions: In this 12-month, placebo-controlled trial, oral nicotinamide therapy did not lead to lower numbers of keratinocyte cancers or actinic keratoses in immunosuppressed solid-organ transplant recipients. (Funded by the National Health and Medical Research Council; ONTRANS Australian New Zealand Clinical Trials Registry number, ACTRN12617000599370.).
    MeSH term(s) Humans ; Australia ; Carcinoma, Basal Cell/etiology ; Carcinoma, Basal Cell/prevention & control ; Carcinoma, Squamous Cell/etiology ; Carcinoma, Squamous Cell/prevention & control ; Chemoprevention ; Keratosis, Actinic/etiology ; Keratosis, Actinic/prevention & control ; Niacinamide/administration & dosage ; Niacinamide/therapeutic use ; Quality of Life ; Skin Neoplasms/etiology ; Skin Neoplasms/prevention & control ; Transplant Recipients ; Immunocompromised Host ; Organ Transplantation/adverse effects ; Antineoplastic Agents/administration & dosage ; Antineoplastic Agents/therapeutic use ; Ultraviolet Rays/adverse effects
    Chemical Substances Niacinamide (25X51I8RD4) ; Antineoplastic Agents
    Language English
    Publishing date 2023-03-01
    Publishing country United States
    Document type Clinical Trial, Phase III ; Journal Article ; Randomized Controlled Trial
    ZDB-ID 207154-x
    ISSN 1533-4406 ; 0028-4793
    ISSN (online) 1533-4406
    ISSN 0028-4793
    DOI 10.1056/NEJMoa2203086
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ua VI Zs.34: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top